Moderna on X: "We have submitted a request for emergency use authorization (EUA) for our Omicron-targeting bivalent #COVID19 #vaccine, mRNA-1273.222, in children and adolescents 12 to 17 years of age to the
FDA Authorizes Moderna Pfizer BioNTech Bivalent COVID 19 Booster Doses
Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results | Nature Medicine
dinero.com.sv - Moderna receives FDA clearance for emergency use of Covid-19 booster vaccine
Moderna seeks FDA nod for Omicron-targeted COVID shot for adolescents, younger kids | Reuters
Moderna on X: "A Phase 2/3 trial for mRNA-1273.222 is currently underway. We have rapidly scaled manufacturing of mRNA-1273.222 to be ready, if authorized, to deliver doses in September. https://t.co/AQG4hfwNe6" / X
Moderna on X: "ANNOUNCEMENT: The U.S. government has secured 66 million doses of our #COVID19 #vaccine booster candidate, mRNA-1273.222, a bivalent booster candidate containing Spikevax™ plus the Omicron BA.4/5 strain mRNA. Read
Moderna COVID19 Bivalent vaccine (Original and Omicron BA.4/BA.5)
With 34 Vaccine Programs in Development, Moderna Eyes Global Launches | BioSpace
Moderna on X: "In a Phase 2/3 trial in over 500 adults, mRNA-1273.222, induced significantly higher neutralizing antibody titers against BA.4/BA.5 compared to a booster dose of mRNA-1273. Read more: https://t.co/CPnxL03nZW https://t.co/ODihw6qtsQ" /
Covid Booster: US to Buy $1.7 Billion of Moderna Omicron-Specific Vaccine (MRNA) - Bloomberg
Moderna says new booster effective against BA.4/BA.5 subvariants | CTV News
CDC Recommends Bivalent COVID 19 Boosters
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice | Nature Medicine
/cloudfront-us-east-2.images.arcpublishing.com/reuters/TCSHY2P5Y5IZLADCIBDXST7MFQ.jpg "Moderna's Omicron shots shows better immune response than original COVID vaccine | Reuters")
Moderna's Omicron shots shows better immune response than original COVID vaccine | Reuters
Moderna Submits Omicron-targeting Bivalent Booster Vaccine | RT
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant | bioRxiv
Moderna on X: "ANNOUNCEMENT 📢: The first participant has been dosed in a Phase 2/3 trial of mRNA-1273.222, a bivalent #COVID19 #booster vaccine candidate targeting the original and #Omicron BA.4/5 strains of
Trial Details
U.S. government places $1.74B order for Moderna's new Covid-19 vaccine boosters - MedCity News
Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results | Nature Medicine
EMA accepts Moderna's CMA submission for Covid-19 vaccine
Omicron-tailored shots show better response than original COVID vaccine: Moderna | Mint
Moderna is padding the case for its bivalent COVID-19 booster
